Table of Contents
Oncology drugs are essential in the treatment of various cancers. They work by targeting specific molecules involved in the growth and spread of cancer cells. Understanding the pharmacological classes of these drugs helps healthcare professionals choose the most effective treatment strategies.
Alkylating Agents
Alkylating agents work by adding alkyl groups to DNA, which prevents cancer cells from dividing and leads to cell death. They are used in many types of cancers, including leukemia, lymphoma, and solid tumors.
- Cyclophosphamide
- Chlorambucil
- Busulfan
- Melphalan
Antimetabolites
Antimetabolites interfere with DNA and RNA synthesis by mimicking normal cellular metabolites. They are particularly effective against rapidly dividing cancer cells.
- Methotrexate
- 5-Fluorouracil (5-FU)
- Mercaptopurine
- Cytarabine
Topoisomerase Inhibitors
These drugs inhibit topoisomerase enzymes, which are crucial for DNA replication. Their inhibition causes DNA damage and cell death.
- Topotecan
- Irinotecan
- Etoposide
- Doxorubicin
Mitotic Inhibitors
Mitotic inhibitors disrupt microtubule function, preventing cancer cells from successfully completing mitosis. They are often used in breast, lung, and ovarian cancers.
- Vincristine
- Vinblastine
- Paclitaxel
- Docetaxel
Chemotherapy Combination Strategies
Combining drugs from different classes can enhance treatment efficacy and reduce resistance. Common regimens include:
- CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)
- FOLFOX (Folinic acid, 5-FU, Oxaliplatin)
- ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)
Targeted Therapies and Immunotherapies
In addition to traditional chemotherapy, targeted therapies and immunotherapies are increasingly used to treat cancers more precisely, often with fewer side effects.
- Tyrosine kinase inhibitors (e.g., Imatinib)
- Monoclonal antibodies (e.g., Trastuzumab)
- Immune checkpoint inhibitors (e.g., Pembrolizumab)
Understanding the pharmacological classes of oncology drugs aids in designing effective treatment plans and improving patient outcomes.